UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $28.53 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,411,466 shares of the company's stock after acquiring an additional 104,288 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.33% of Roivant Sciences worth $28,528,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Zimmer Partners LP bought a new stake in Roivant Sciences during the 4th quarter worth approximately $2,992,000. Vestal Point Capital LP acquired a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $14,788,000. Vident Advisory LLC boosted its holdings in shares of Roivant Sciences by 98.7% in the fourth quarter. Vident Advisory LLC now owns 32,039 shares of the company's stock valued at $379,000 after buying an additional 15,918 shares during the period. Tyro Capital Management LLC increased its position in shares of Roivant Sciences by 20.1% during the fourth quarter. Tyro Capital Management LLC now owns 2,108,283 shares of the company's stock worth $24,941,000 after acquiring an additional 353,307 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in shares of Roivant Sciences by 8.4% during the fourth quarter. Rafferty Asset Management LLC now owns 722,429 shares of the company's stock worth $8,546,000 after acquiring an additional 55,960 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Price Performance

ROIV stock traded down $0.14 during mid-day trading on Wednesday, reaching $10.62. The company had a trading volume of 6,305,087 shares, compared to its average volume of 5,578,906. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of -70.80 and a beta of 1.23. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The stock has a 50 day simple moving average of $10.52 and a two-hundred day simple moving average of $11.03.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,116,345 shares of the company's stock, valued at approximately $11,409,045.90. This trade represents a 8.22% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,223,959 shares of company stock valued at $13,450,035. 7.90% of the stock is owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.